-
Mashup Score: 49Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - 12 day(s) ago
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - 13 day(s) ago
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! https://t.co/R395wFoGeg
-
-
Mashup Score: 7ClinicalTrials.gov - 2 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
@NoopurRajeMD @MGHCancerCenter Bela maf is 1.9 mg/kg q8 weeks, combined with isatuximab, pomalidomide, dexamethasone. So hoping that there will be multiple synergies to maximize efficacy, and spacing out the dosing and decreasing the dose of bela maf to improve the ocular AE profile https://t.co/rB7ZweijsP
-
-
Mashup Score: 5Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma - 5 month(s) ago
Key PointsMS provides significant prognostic information in the maintenance setting and complements BM MRD in multiple myeloma.Without the aid of a baselin
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The table is from a commentary that accompanies @bdermanmd excellent study looking at the performance of EXENT in the ATLAS study https://t.co/wIQN5oXOnE and how it can complement bone marrow-based MRD assessments
-
-
Mashup Score: 12DARATUMUMAB (DARA) + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD)... by Prof. Philippe Moreau - 8 month(s) ago
EHA Library; Moreau P. Jun 13 2024; 422308;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
@End_myeloma @MyelomaTeacher @Rfonsi1 @VincentRK @DrOlaLandgren Here's the link for the updated results of CASSIOPEIA https://t.co/1eXs2r1Amu
-
-
Mashup Score: 0
Multiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to define the prevalence and risk factors of MGUS in a large cohort representative of the US …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@ManniMD1 @Drjhoffmanmiami I think the testing for MGUS was done systematically in the NHANES study. More info here in the original prevalence of MGUS in the NHANES publication by @DrOlaLandgren https://t.co/wsHHtvFSv2 https://t.co/isQZhf8GuQ
-
-
Mashup Score: 2Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy - 1 year(s) ago
Introduction: With the availability of multiple therapy classes targeting BCMA for multiple myeloma (MM), data are needed to understand effective treatment (tx)
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Cilta-cel data after prior BCMA therapy presented by @CohenAd_MMdoc #ASH22 https://t.co/goN239hZES and published https://t.co/7K25gWmg7K
-
-
Mashup Score: 33
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I Hematology Disease Topics & Pathways: Diseases, therapy sequence, Therapies, Lymphoid Malignancies Larysa Sanchez, MD 1 *, Carolina Schinke, MD 2, Amrita Krishnan, MD 3, Jésus G Berdeja, MD 4, Niels W.C.J van de Donk, MD, PhD 5 *, María Victoria Mateos, MD, PhD 6, Ajai Chari, MD 7 *, Samir Parekh, MD 8, Tarek H. Mouhieddine, MD 9, Sundar Jagannath, MD 8, Nizar J Bahlis, MD 10, Cyrille Touzeau, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Some emerging data on efficacy of anti-BCMA CAR T-cell after talquetamab presented by Larysa Sanchez at #ash23 https://t.co/NQhaZjfBS3 showing respectable response rates (though very interested in PFS): https://t.co/r0nEovSZyU
-
-
Mashup Score: 1
Free Light Chain Assay Drift: Potential for Misdiagnosis?
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
This study also highlights an increasing appreciation of the phenomenon of "free light chain assay drift" over the years noted here https://t.co/Q7GpnqZZ2g
-
-
Mashup Score: 2
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
And also noted here by @MinnemaMonique in https://t.co/oMuqV8NNv4 https://t.co/4HwuJYcByB
-
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! https://t.co/R395wFoGeg